ESG206

Phase 2Small molecule

SShanghai Escugen Biotechnology Co., Ltd

ESG206 is one of 54 small molecule programs targeting Systemic Lupus Erythematosus (SLE). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus Erythematosus (SLE)Not yet recruiting

Immune ThrombocytopeniaRecruiting

Systemic Lupus Erythematosus (SLE)Phase 2

Not yet recruiting

Immune ThrombocytopeniaPhase 2

Recruiting

Competition

Competitive Landscape

56 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

14 2

Rituxan

Roche

Approved

13 3

Decadron

AAspen Global Incorporated

Approved

21 4

Plaquenil

Jazz Pharmaceuticals

Approved

1 5

Oncovin

Eli Lilly

Approved

1 6

Rayos

RRoxane Laboratories

Approved

6 7

Imuran

LLegacy Health System

Approved

1 8

Vyvgart

Argenx

Phase 3

6 9

Doptelet

AAkarx

Phase 3

6 10

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Immune Thrombocytopenia

NCT06853444

Q2 2028

Phase 2Not yet recruiting

Sjogren Syndrome

NCT07375524

Q3 2028

Phase 2Not yet recruiting

Systemic Lupus Erythematosus (SLE)

NCT07760155

Clinical

Trials by Indication[1]

B-cell Lymphoid Malignancies2 trials

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

Withdrawn·SShanghai Escugen Biotechnology Co., Ltd·Phase 1·NCT05263739

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Completed·SShanghai Escugen Biotechnology Co., Ltd·Phase 1·NCT05822843·13 enrolled

Sjogren syndrome1 trial

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

Not yet recruiting·SShanghai Escugen Biotechnology Co., Ltd·Phase 2·NCT07375524·40 enrolled

Immune Thrombocytopenia1 trial

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

Recruiting·SShanghai Escugen Biotechnology Co., Ltd·Phase 1/2·NCT06853444·84 enrolled

Systemic Lupus Erythematosus (SLE)1 trial

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

Not yet recruiting·SShanghai Escugen Biotechnology Co., Ltd·Phase 2·NCT07760155·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ESG206. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ESG206 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ESG206. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Escugen Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Escugen Biotechnology Co., Ltd

ESG206

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q3 2028

Trials by Indication[1]

B-cell Lymphoid Malignancies2 trials

Sjogren syndrome1 trial

Immune Thrombocytopenia1 trial

Systemic Lupus Erythematosus (SLE)1 trial

References

Drug Info

Quick Facts

Related News